Searle's Cytotec
Executive Summary
FDA's Gastrointestinal Drugs Advisory Cmte. will discuss company's supplemental NDA for Cytotec (misoprostol) for prevention of NSAID-induced peptic ulceration at panel's Sept. 15-16 meeting. While Searle's NDA for short-term treatment of duodenal ulcer, pending since 1984, appears to be hung up, the concomitant use with NSAID's has a 1-A rating at FDA and looks to be moving toward approval. Panel will also review Pharmacia's Dipentum (olsalazine) for prolongation of remission between acute attacks of ulcerative colitis, treatment of mild ulcerative colitis, and as adjunctive therapy for moderate to severe ulcerative colitis.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.